Phase II: Development of Low-Cost, Shelf-Stable Treatment for Tuberculosis

Via Therapeutics, Llc, Austin TX

Investigators

Abstract

To develop and test a low-cost, easy-to-administer drug formulation intended for use in treating rifampicin-resistant pulmonary tuberculosis in pediatric patient populations.